Immuno Research Inc.
TSX VENTURE : IRI

May 16, 2006 16:55 ET

Immuno Research Retains Ascenta Capital Partners Inc. to Provide Investor Relations Services

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 16, 2006) - Immuno Research Inc. (TSX VENTURE:IRI) is pleased to announce it has retained Ascenta Capital Partners Inc. of Vancouver, BC, to provide investor relations and financial communications services.

Ascenta will receive a monthly retainer of $5,500 for a 12-month term subject to termination by either party with 60 days written notice. Immuno will also issue as compensation to Ascenta an option to purchase 75,000 common shares immediately at an exercise price of $0.50 per share which will be effective for a period ending 30 days after the termination of the contract, and a further 75,000 at a mutually agreed date and price. The options granted will vest in accordance with TSX Venture Exchange guidelines and Immuno's stock option plan. This agreement is subject to regulatory approval.

About Ascenta Capital Partners Inc.

Ascenta is a leading provider of investor relations services to public companies in Canada. Ascenta's strength is its disciplined approach to the development and execution of strategic, customized investor relations programs and services.

On behalf of the Board of Directors, Steven Pettigrew, Chief Financial Officer.

The Company seeks Safe Harbour.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Immuno Research Inc.
    John Mason
    (604) 807-8694
    (604) 926-1485 (FAX)
    jmason99@shaw.ca
    or
    Ascenta Capital Partners Inc.
    Francis Reynolds
    Investor Relations
    (604) 684-4743 ext. 28 or Toll Free: 1-866-684-4743 ext. 28
    francis@ascentacapital.com